ALRN Projected Dividend Yield
Aileron Therapeutics Inc ( NASDAQ : ALRN )Aileron Therapeutics is a clinical stage chemoprotection oncology company. Co.'s product candidate, ALRN-6924, is a MDM2/MDMX dual inhibitor that utilizes its proprietary peptide drug technology. When used as a chemoprotective agent, ALRN-6924 is designed to activate p53, which in turn upregulates p21, an inhibitor of the cell replication cycle. ALRN-6924 is a chemoprotective agent in clinical development to employ a biomarker strategy, in which Co. focuses on treating patients with p53-mutated cancers. 20 YEAR PERFORMANCE RESULTS |
ALRN Dividend History Detail ALRN Dividend News ALRN Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |